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Marrow Transplantation with High-Dose
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Effect of HLA Disparity on Outcome
Yvette L. Kasamon,1 Leo Luznik,1 Mary S. Leffell,1 Jeanne Kowalski,1 Hua-Ling Tsai,1
Javier Bolan˜os-Meade,1 Lawrence E. Morris,2 Pamela A. Crilley,3 Paul V. O’Donnell,4
Nancy Rossiter,1 Carol Ann Huff,1 Robert A. Brodsky,1 William H. Matsui,1 Lode J. Swinnen,1
Ivan Borrello,1 Jonathan D. Powell,1 Richard F. Ambinder,1 Richard J. Jones,1 Ephraim J. Fuchs1Although some reports have found an association between increasing HLA disparity between donor and
recipient and fewer relapses after allogeneic blood or marrow transplantation (BMT), this potential benefit
has been offset by more graft-versus-host disease (GVHD) and nonrelapse mortality (NRM). However, the
type of GVHD prophylaxis might influence the balance between GVHD toxicity and relapse. The present
study analyzed the impact of greater HLA disparity on outcomes of a specific platform for nonmyeloablative
(NMA), HLA-haploidentical transplantation. A retrospective analysis was performed of 185 patients with he-
matologic malignancies enrolled in 3 similar trials of NMA, related donor, haploidentical BMT incorporating
high-dose posttransplantation cyclophosphamide for GVHD prophylaxis. No significant association was
found between the number of HLA mismatches (HLA-A, -B, -Cw, and -DRB1 combined) and risk of acute
grade II-IVGVHD (hazard ratio [HR]5 0.89; P5.68 for 3-4 vs fewer antigenmismatches). Moremismatching
also had no detrimental effect on event-free survival (on multivariate analysis, HR5 0.60, P5 .03 for 3-4 vs
fewer antigen mismatches and HR 5 0.55, P 5 .03 for 3-4 vs fewer allele mismatches). Thus, greater HLA
disparity does not appear to worsen overall outcome after NMA haploidentical BMTwith high-dose post-
transplantation cyclophosphamide.
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Historically, donor-recipient HLA compatibility
has been the leading predictor of outcome after allo-
geneic blood or marrow transplantation (BMT). In-
creasing degrees of HLA mismatch at either the
antigen level or the allele level have been repeatedly as-1Johns Hopkins University, Baltimore, Maryland; 2BMT
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6/j.bbmt.2009.11.011sociated with worse overall outcomes in series of
myeloablative (MA) related or unrelated donor BMT
for hematologic malignancies [1-7]. The reported
effect of HLA disparity on relapse risk varies [2,3,5].
Although some studies have found a lower relapse
risk with increasing degrees of HLA mismatch or spe-
cific mismatches, suggesting a graft-versus-tumor
(GVT) effect, this generally has been offset by higher
rates of graft-versus-host disease (GVHD), graft fail-
ure, and nonrelapse mortality (NRM) [1-7]. Thus,
although one or more partially-HLA mismatched
(HLA-haploidentical) first-degree relatives can be
readily identified inmost patients who lack a histocom-
patible donor, the toxicity of such transplants has
prevented many centers from pursuing this approach.
High-dose cyclophosphamide (Cy), when admin-
istered in a narrow window after transplantation, de-
pletes alloreactive T cells from the donor and host
and can inhibit both GVHD and graft rejection [8-
16]. As a form of drug-induced immunologic tolerance
[17], the strategy of giving high-dose Cy after
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totoxic sensitivity of proliferating, alloreactive T cells
over nonalloreactive, resting T cells to being killed by
a DNA-damaging agent [12]. Recently, high-dose
Cy on days 3 and 4 after MA, HLA-matched related
or unrelated donor BMT was reported to provide
effective GVHD prophylaxis without the addition
of a calcineurin inhibitor [14]. In early-phase trials of
nonmyeloablative (NMA), HLA-haploidentical BMT,
incorporation of posttransplantation Cy, tacrolimus,
and mycophenolate mofetil (MMF) was associated
with timely and stable engraftment. Most importantly,
this approach carried acceptable rates of acute GVHD
(aGVHD), chronic GVHD (cGVHD), and NRM that
parallel those seen inNMAHLA-matched transplanta-
tion [15,16,18]. We postulated that the impact of do-
nor-recipient HLA disparity on GVHD toxicity and
overall outcome could vary depending on the type of
posttransplantation immunosuppression. These prom-
ising results prompted us to analyze the effects of HLA
disparity on outcomes of NMA, haploidentical BMT
incorporating high-dose posttransplantation Cy.PATIENTS AND METHODS
Eligibility
We retrospectively analyzed 185 consecutive pa-
tients enrolled in 3 similar clinical trials of NMA,
related donor, partiallyHLA-mismatched BMT incor-
porating high-dose posttransplantationCy for the pro-
phylaxis of GVHD and graft rejection. Of these
patients, 144were treated at JohnsHopkinsUniversity,
13 were treated at participating centers (BMT Group
of Georgia and Hahnemann University Hospital),
and 28were treated at theFredHutchinsonCancerRe-
search Center. The protocol received institutional re-
view board approval, and all participants provided
signed informed consent. The patients were adults or
children with poor-risk or advanced hematologic ma-
lignancies who were not candidates for autologous or
MA allogeneic BMT or who had relapsed despite
this. Eligibility criteria included an Eastern Coopera-
tive Oncology Group performance status score\2 or
a Karnofsky or Lansky-Play score $60, adequate he-
patic function (total bilirubin #3.0 mg/dL or absence
of clinically significant liver disease), left ventricular
ejection fraction $35%, and adequate pulmonary
function (forced expiratory volume in 1 second
[FEV1] and forced vital capacity [FVC] $40% of pre-
dicted and $60% of predicted in patients receiving
previous thoracic ormantle irradiation, or diffusing ca-
pacity of the lung for carbon monoxide [DLCO]
$35%). Diagnoses included poor-risk acute leukemia
(eg, adverse cytogenetics, age.60 years, high present-
ing white blood cell count, mixed lineage leukemia,
delayed response or nonresponse to induction therapy)in first complete remission; acute leukemia in second or
subsequent complete remission; myelodysplastic syn-
drome with or without leukemic transformation; inter-
feron- or imatinib-refractory chronic myelogenous
leukemia (CML) in first chronic phase or non-blast
crisis CML beyond first chronic phase; other chronic
myeloproliferative disorders, including chronicmyelo-
monocytic leukemia, myeloid metaplasia, and polycy-
themia vera; Hodgkin lymphoma; non-Hodgkin
lymphoma; chronic lymphocytic leukemia; and multi-
ple myeloma.
Donors were first-degree relatives who were iden-
tical at one HLA haplotype and mismatched at one or
more loci of the unshared haplotype. Molecular typing
was at an allele or allele group level for HLA-A, -B,
-Cw, -DRB1, and -DQB1, as described previously
[16]. Rare cases were omitted from analyses of allele
mismatching because of insufficient resolution but
were evaluable for antigen mismatching. Factors in
donor prioritization included HLA cross-match
compatibility and ABO compatibility.
Treatment
The transplantation regimen and outcomes of 67 of
the patients have been reported previously [16]. All pa-
tients receivedCy (14.5mg/kg i.v. on days26 and25),
fludarabine (30 mg/m2 i.v. on days26 to22, adjusted
for renal function), total body irradiation (200 cGy on
day 21), and T cell-replete bone marrow infusion (on
day 0). After transplantation, high-dose Cy (50 mg/kg
i.v.) was administered once on day 3 or once daily on
days 3 and 4, with mesna (80% or 100% dose of Cy,
in divided doses). Cy was dosed according to ideal or
adjusted body weight, unless the actual weight was
less than the ideal weight. One day later, all patients
beganMMF (maximum3g orally daily in divided doses
up to day 35), tacrolimus, and filgrastim (5 mg/kg/day
s.c. until neutrophil recovery) [16]. In those receiving
one dose of posttransplantationCy (n548), tacrolimus
was given until day 50 (n 5 10) or day 180 (n 5 38) in
the absence of GVHD. In those receiving 2 doses of
posttransplantation Cy (n 5 137; 74%), tacrolimus
with a target level of 5-15 ng/mL was given until day
180 in the absence of GVHD.
Endpoints
HLA mismatch (assigned by M.S.L.) in the graft-
versus-host (GVH) direction was defined as the
presence of host antigens or alleles not shared by the
donor. HLA mismatch in the host-versus-graft
(HVG) direction was defined as the presence of donor
antigens or alleles not shared by the host. All antigen
disparities were also counted as allele disparities.
GVHD was analyzed according to GVH direction
mismatching, graft rejection was analyzed according
to HVG direction mismatching, and disease and
484 Biol Blood Marrow Transplant 16:482-489, 2010Y. L. Kasamon et al.survival outcomes were analyzed according to either
direction or a particular direction as specified.
Disease and survival endpoints were defined as
follows. aGVHD was graded according to the Key-
stone criteria [19] and confirmed by biopsy when possi-
ble. First-line therapy for skin aGVHD consisted of
methylprednisolone 1-2.5 mg/kg/day i.v. or predni-
sone equivalent, whereas patients with visceral
aGVHD received methylprednisolone in combination
with other immunosuppressants, such as tacrolimus
with or without MMF. Eligible patients with aGVHD
were treated on protocol BMT CTN 0302 [20].
cGVHD was diagnosed and graded according to both
National Institutes of Health and Seattle standard
guidelines [21,22].
Graft failure was defined as persistent lack of donor
chimerism (ie,\5% donor) by day 30 or day 60 post-
transplantation. Donor chimerism was determined in
blood or bone marrow by restriction fragment length
polymorphisms, polymerase chain reaction of variable
nucleotide tandem repeats, or X- and Y- chromosome
fluorescence in situ hybridization.
Statistical Methods
Event-time distributions for overall survival (OS)
and event-free survival (EFS), measured from the day
of transplantation,were estimatedby theKaplan-Meier
method and compared using Cox proportional hazard
models. An event was defined as relapse, progression,
or death. The simultaneous effect of 2 or more factors
was studied with multivariate proportional hazards
models. Cumulative incidences of relapse,NRM, grade
II-IV aGVHD, and cGVHD,measured from the day of
transplantation, were estimated using competing-risk
analyses [23], and prognostic factors for these end-
points were analyzed using proportional hazards
models for competing risks [24]. For competing-risk
analyses, death without relapse or progression was con-
sidered a competing risk for relapse, relapsewas consid-
ered a competing risk for NRM, and graft failure,
relapse, and death without GVHD were considered
competing risks for GVHD. A case of donor-derived
leukemiawas also scored as an event and as a competing
risk where applicable.
For evaluating differences in group characteristics,
Wilcoxon’s test was used for continuous variables and
the c2 test or Fisher’s exact test for cell counts\5 was
used for categorical variables. All P values are 2-sided
and unadjusted formultiple comparisons. All statistical
analyses were performed using R version 2.6.2 [25].RESULTS
Patients and Overall Outcomes
Table 1 summarizes baseline characteristics of the
patients and transplants for the entire group (n5 185)and by the number of HLA mismatches. The median
patient age was 50 years, similar proportions of pa-
tients had lymphoid (57%) and myeloid diseases, and
27% had undergone a previous BMT. The actuarial
EFS at 1 year was 35%, with a median follow-up of
20 months in those without an event and 6 months
overall (range, \1 to 71 months). The cumulative
incidence of NRM was 6% at day 100 and 15% at
1 year. Graft failure with or without residual bone
marrow malignancy occurred in 29 of 177 evaluable
patients (16%). The cumulative incidence of grade
II-IV aGVHD and cGVHD was 31% and 15%,
respectively.
Composite Analysis of Total HLA Mismatches
Table 2 presents a univariate analysis of total mis-
matches at HLA-A, -B, -Cw, and -DRB1 in relation to
transplantation outcomes. On univariate analysis, hav-
ing 3 or 4 total antigen mismatches in any direction
was not associated with inferior EFS (hazard ratio
[HR]5 0.67; P5 .09) compared with having fewer an-
tigen mismatches (Figure 1A). No statistically signifi-
cant difference was found in the cumulative
incidence of relapse or of NRM (Figure 1B). Of
note, having more antigen mismatches was not associ-
ated with a statistically significant difference in the risk
of grade II-IV aGVHD (HR 5 0.89; P 5 .68)
(Figure 1C). Analyses of cGVHD are not presented,
because this occurred in only 26 patients without com-
peting risks.
We also performed a univariate analysis of out-
comes according to the total number of antigen
mismatches treated as continuous covariates (ie, 0, 1,
2, 3, or 4mismatches). For EFS, each additional degree
of mismatch in any direction was nondetrimental, with
an observed protective effect (HR 5 0.80; 95% confi-
dence interval [CI] 5 0.66-0.96; P 5 .02). This ap-
proach revealed no statistically significant difference
in the cumulative incidence of relapse (HR 5 0.86;
95% CI 5 0.69-1.06; P 5 .16) or NRM (HR 5 0.82;
95%CI5 0.56-1.21; P5 .33), nor a statistically signif-
icant difference in the risk of grade II-IV aGVHDwith
each additional degree of GVH-direction mismatch
(HR 5 0.87; 95% CI 5 0.70-1.09; P 5 .24).
Table 3 presents a univariate analysis of other vari-
ables that could influence EFS, including age, disease
type, donor characteristics, and graft characteristics.
There was no statistically significant difference in
EFS between patients age 50-59 years and those age
\50 years (data not shown), whereas patient age $60
years was associated with an inferior EFS (HR 5
1.64; P 5 .01), as was having a female donor for
amale recipient (HR5 1.47; P5 .04). The adverse im-
pact on EFS was not accounted for by a significantly
increased risk of grade II-IV aGVHD (for age $60,
HR 5 1.18 for aGVHD, 95% CI 5 0.66-2.09, P 5
.57; for female donor/male recipient, HR 5 0.76,
Table 1. Patient Characteristics
Variable Entire Group (n 5 185) 0-2 Antigen Mismatches (n 5 26)*,† 3-4 Antigen Mismatches (n 5 159)*,‡ P
Patient age, years, median (range) 50 (1-71) 52 (20-66) 49 (1-71) .54
Male sex, n (%) 117 (63%) 13 (50%) 104 (65%) .20
Diagnosis, n (%)
Lymphoid 106 (57%) 17 (65%) 89 (56%) .51
ALL§ 16 (9%) – – –
Hodgkin lymphoma 25 (13.5%) – – –
CLL 14 (8%) – – –
Multiple myeloma¶ 8 (4%) – – –
Non-Hodgkin lymphomak 43 (23%) – – –
Myeloid 78 (42%) 9 (35%) 69 (43%) –
AML** 49 (26%) – – –
MDS 11 (6%) – – –
CML†† 12 (6%) – – –
CMML 5 (3%) – – –
Polycythemia vera with myelofibrosis 1 – – –
Biphenotypic leukemia 1 0 1 –
Previous BMT, n (%)‡‡ 50 (27%) 10 (38%) 40 (25%) .24
Donor age, years, median (range) 42 (14-73) 45 (23-65) 42 (14-73) .25
Donor relationship, n (%)
Mother 18 (10%) 0 18 (11%) .08
Father 16 (9%) 3 (12%) 13 (8%) –
Sibling 97 (52%) 15 (58%) 82 (52%) –
Child 54 (29%) 8 (31%) 46 (29%) –
Female donor/male recipient, n (%) 48 (26%) 5 (19%) 43 (27%) .55
CMV serostatus, patient/donor, n §§
Negative/negative 63 (34%) 11 (44%) 52 (33%) –
Negative/positive 34 (18%) 4 (16%) 30 (19%) –
Positive/negative 43 (23%) 5 (20%)§§ 38 (24%) –
Positive/positive 44 (24%) 5 (20%)§§ 39 (25%) –
CMV mismatch 77 (42%)§§ 9 (36%)§§ 68 (43%) .67
Cell dose infused, median (range)
CD34+ cells  106/kg 3.9 (1.6-12.8) 3.9 (1.6-12.8) 3.8 (1.7-12.6) .82
CD3+ cells  107/kg 3.6 (0.5-9.8)¶¶ 3.6 (1.8-5.9) 3.7 (0.5-9.8)¶¶ .68
Two doses of posttransplantation Cy, n (%) 137 (86%) 15 (58%) 122 (77%) .07
Class I and II mismatches, median (range)*
Antigen mismatches 4 (0-4) – – –
Allele mismatches 4 (1-4) – – –
ALL indicates acute lymphoblastic leukemia or lymphoblastic lymphoma; CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leuke-
mia; BMT, blood or marrow transplantation; CMV, cytomegalovirus; CLL, chronic lymphocytic leukemia; AML, acute myelogenous leukemia; MDS,
Myelodysplastic syndrome; Cy, cyclophosphamide.
*Mismatching in any direction; composite of HLA-A, -B, -Cw, and -DRB1. HLA-DQB1 was typed, but mismatching was not included in this analysis.
†Two donor-recipient pairs had 0 antigen mismatches at HLA-A, -B, -Cw, and -DRB1, but were mismatched at the allele level, with one of these also
mismatched for a -DQB1 antigen; 8 donor-recipient pairs had 1 antigen mismatch; 16 had 2 antigen mismatches.
‡A total of 57 donor-recipient pairs had 3 antigen mismatches; 102 had 4 antigen mismatches.
§Fourteen pre-B cell, 2 T cell, and 1 T cell with later features of primitive leukemia.
¶One with plasma cell leukemia.
kExcluding CLL, multiple myeloma, and lymphoblastic lymphoma. Thirteen patients with follicular lymphoma, including 1 with previous large B cell lym-
phoma; 7 with diffuse large B cell lymphoma or large B cell lymphoma, including 2 transformations and 1 diffuse large B cell lymphoma evolved from
follicular grade 3 lymphoma; 7 with peripheral T cell lymphoma; 10 with mantle cell lymphoma; 2 with T cell prolymphocytic leukemia; and 1 patient
each with null cell type anaplastic large cell lymphoma, marginal zone lymphoma, Waldenstrom macroglobulinemia, and hairy cell leukemia.
**De novo in 36 cases.
††One case of CML had a concurrent diagnosis of MDS.
‡‡Forty-eight autologous, 2 allogeneic. Includes 5 patients who underwent transplantation for treatment-related MDS/AML arising after previous BMT
for lymphoma.
§§In 1 case donor was CMV negative with patient serostatus unknown.
¶¶Unknown in 1 case.
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ysis of EFS that included these variables, having 3 or 4
total antigen mismatches compared with fewer mis-
matches was not detrimental and appeared to be pro-
tective (HR 5 0.60; P 5 .03) (Table 4).
No statistically significant differences in patient or
transplant characteristics were found between those
with more versus fewer total antigen mismatches
(Table 1). In the group with more antigen mismatches,
there was a tendency toward more patients receivinga maternal graft or receiving 2 doses of posttransplan-
tation Cy. Including these factors in this multivariate
model did not change the outcome (data not shown).
Similarly, the presence of a greater number of
allele mismatches was not associated with inferior out-
comes. Having more allele mismatches was associated
with a tendency toward lower relapse risk on univariate
analysis (HR 5 0.58; P 5 .11 for 3 or 4 vs fewer mis-
matches) (Table 2), and was not detrimental and
appeared to be protective on multivariate analysis
Table 2. Univariate Analysis of HLA Disparity in Relation to Transplantation Outcomes
Variable (Reference)
Direction of
Mismatch n*
HR for Acute
GVHD (95% CI)
P for
Acute GVHD
HR for Relapse
(95% CI)
P for
Relapse
HR for NRM
(95% CI)
P for
NRM
HR for EFS
(95% CI)
P for
EFS
Total antigen mismatch,
3-4 (vs 0-2)
Any 159 (26) – – 0.79 (0.45-1.41) .43 0.61 (0.26-1.47) .27 0.67 (0.43-1.07) .09
GVH 136 (49) 0.89 (0.50- 1.58) .68 0.86 (0.56-1.33) .50 0.76 (0.35-1.67) .50 0.81 (0.56-1.18) .27
HVG 137 (48) – – 0.65 (0.42-1.00) .05 1.06 (0.45-2.45) .90 0.69 (0.47-1.00) .05
Total allele mismatch,
3-4 (vs 1-2)
Any 165 (17) – – 0.58 (0.30-1.14) .11 0.86 (0.27-2.75) .80 0.58 (0.34-1.00) .05
GVH 152 (30) 1.03 (0.51- 2.09) .94 0.70 (0.42-1.18) .18 1.16 (0.41-3.33) .78 0.75 (0.48-1.19) .22
HVG 153 (29) – – 0.54 (0.32-0.91) .02 1.08 (0.38-3.08) .88 0.57 (0.37-0.89) .01
Class I antigen mismatch,
2-3 (vs 0-1)
Any 166 (19) – – 0.55 (0.30-0.98) .04 0.98 (0.30-3.22) .98 0.54 (0.32-0.89) .02
GVH 153 (32) 0.84 (0.43-1.61) .59 0.70 (0.44-1.11) .13 1.29 (0.45-3.67) .63 0.78 (0.50-1.20) .26
HVG 152 (33) – – 0.55 (0.33-0.91) .02 1.33 (0.46-3.85) .59 0.60 (0.39-0.92) .02
DRB1 antigen mismatch,
1 (vs 0)
Any 153 (32) – – 0.76 (0.47-1.22) .26 0.99 (0.38-2.59) .98 0.78 (0.51-1.21) .27
GVH 131 (54) 1.06 (0.60-1.88) .84 0.65 (0.43-0.99) .04 0.87 (0.40-1.93) .74 0.62 (0.43-0.89) .009
HVG 137 (48) – – 0.93 (0.61-1.40) .71 0.69 (0.31-1.52) .35 0.82 (0.56-1.20) .31
EFS indicates event-free survival; GVHD, graft-versus-host disease; HR, hazard ratio; HVG, host-versus-graft; NRM, nonrelapsemortality; CI, confidence
interval.
*Number of patient-donor pairs with more mismatches (vs the reference category of fewer mismatches).
486 Biol Blood Marrow Transplant 16:482-489, 2010Y. L. Kasamon et al.of EFS (HR 5 0.55; P 5 .03) (Table 4). However, we
found no significantly increased risk of grade II-IV
aGVHD associated with having 3 or 4, as compared
with fewer, total allele mismatches on univariate anal-
ysis (HR 5 1.03; P 5 .94).Total Mismatches According to Vector
Overall outcomes also were analyzed according to
the direction of the mismatch (Table 2). Such anFigure 1. Outcomes according to donor-recipient HLAmismatch. EFS (A) and
of antigen mismatches in either direction. (C), Cumulative incidence of grade II
direction. Cumulative incidences were estimated by competing-risk analysis. A
-DRB1 combined. Ag, antigen; MM, mismatch.analysis helps explore whether the observed effects of
HLA disparity result from imbalances in clinically sig-
nificant mismatches; for example, having more HVG-
direction mismatches may be less clinically significant
than having more GVH-direction mismatches. On
univariate analysis, no statistically significant associa-
tion was found between the total number of antigen
or allele mismatches in the GVH direction (3 or 4 vs
fewer) and relapse, NRM, or EFS (Table 2). In the
HVG direction, more mismatches were associatedcumulative incidences of relapse and NRM (B) according to the number
-IV aGVHD according to the number of antigen mismatches in the GVH
nalyses are based on the number of mismatches at HLA-A, -B, -Cw, and
Table 3. Univariate Analysis of EFS for Variables Other Than
HLA Mismatching
Variable (Reference) n HR (95% CI) P
Patient age $60 years (vs <60 years) 43 (142) 1.64 (1.12-2.41) .01
Lymphoid disease (vs myeloid) 106 (78) 0.81 (0.57-1.14) .22
Donor age $45 years (vs <45 years) 83 (102) 1.01 (0.72-1.43) .94
Female donor/male recipient
(vs other)
48 (137) 1.47 (1.02-2.14) .04
Mother as donor (vs other) 18 (167) 1.18 (0.69-2.03) .54
CMV mismatch (vs CMV match) 77 (107) 0.93 (0.65-1.31) .65
CD34+ dose $3.9  106/kg
(vs <3.9  106/kg)
93 (92) 1.05 (0.74-1.48) .78
CD3+ dose $3.6  107/kg
(vs <3.6  107/kg)
99 (85) 1.22 (0.86-1.72) .26
Two doses of posttransplantation
Cy (vs 1)
137 (48) 0.98 (0.67-1.43) .92
CMV indicates cytomegalovirus; Cy, cyclophosphamide; EFS, event-free
survival; HR, hazard ratio; CI, confidence interval.
Table 4. Multivariate Analysis of EFS
Variable (Reference)* n HR (95% CI) P
Model 1
Total antigen mismatch,
3-4 (vs 0-2)
159 (26) 0.60 (0.38-0.95) .03
Patient age $60 years (vs <60
years)
43 (142) 1.78 (1.20-2.62) .004
Female donor/male recipient
(vs other)
48 (137) 1.60 (1.10-2.34) .01
Model 2
Total allele mismatch,
3-4 (vs 1-2)
165 (17) 0.55 (0.32-0.94) .03
Patient age $60 years (vs <60
years)
42 (140) 1.75 (1.18-2.59) .006
Female donor/male recipient
(vs other)
47 (135) 1.58 (1.08-2.30) .02
Model 3
Class I antigen mismatch,
2-3 (vs 0-1)
166 (19) 0.53 (0.32-0.90) .02
DRB1 antigen mismatch
in GVH direction, 1 (vs 0)
131 (54) 0.55 (0.38-0.80) .002
Patient age $60 years (vs <60
years)
43 (142) 1.96 (1.32-2.92) .001
Female donor/male recipient
(vs other)
48 (137) 1.62 (1.11-2.36) .01
EFS indicates event-free survival; GNH, graft-versus-host; HR, hazard
ratio; CI, confidence interval.
*HLA mismatches are in either direction unless specified otherwise.
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relapse risk and EFS (Table 2). Because of the tight
correlation between GVH- and HVG-direction mis-
matches at single loci, however, their relative contribu-
tions cannot be dissociated.
The probability of graft failure was examined with
respect to the number of antigen mismatches in the
HVG direction. A higher incidence of graft failure (re-
corded as a yes/no) was observed in patients with 3 or 4
antigen mismatches in the HVG direction compared
with thosewith fewermismatches (130 and47 evaluable
patients per group, respectively). The difference was
not statistically significant (odds ratio 5 1.91; 95%
CI5 0.68-5.31;P5 .22), although the analysiswas lim-
ited by the small sample size. Treating the number of
HVG-direction mismatches as continuous covariates
revealed no statistically significant trend with respect
to modeling the probability of graft failure (P5 .62).Mismatch Analysis According to HLA Locus
To further investigate whether the observed non-
deleterious effects of HLA disparity on EFS reflect
a skewing of clinically significant variables, overall
outcomes were analyzed separately at class I and at
HLA-DRB1 (Tables 2 and 4). The presence of 2 or
more class I antigen mismatches in any direction was
associated with a lower risk of relapse on univariate
analysis (HR 5 0.55; P 5 .04) and a lower risk for an
event on multivariate analysis (HR 5 0.53; P 5 .02).
In the GVH direction, univariate analysis revealed
no detrimental effect of more class I antigen mis-
matches on overall outcome (HR 5 0.78; P 5 .26
for EFS) or on the risk of grade II-IV aGVHD (HR
5 0.84; P 5 .59), and showed a tendency toward
a lower risk of relapse (HR 5 0.70; P 5 .13). In the
HVG direction, more class I antigen mismatching also
was associated with a lower risk of relapse (HR5 0.55;
P 5 .02) and a lower risk for an event (HR 5 0.60;
P 5 .02) on univariate analysis.Likewise, HLA-DRB1 antigen mismatching was
not associated with inferior outcomes. On univariate
analysis (Table 2), DRB1 antigen mismatching in the
GVH direction was associated with a lower risk of
relapse (HR 5 0.65; P 5 .04), a similar risk of grade
II-IV aGVHD (HR5 1.06; P5 .84), and an improved
EFS (HR 5 0.62; P 5 .009). On multivariate analysis
of EFS (Table 4), an HLA-DRB1 antigen mismatch
in the GVH direction and 2 or more class I antigen
mismatches in any direction appeared to be protective.DISCUSSION
Increasing degrees of HLA mismatch between
donor and recipient have been repeatedly associated
withgreater toxicity and inferior survival after allogeneic
BMT [1-7]. However, the present analysis suggests that
with nonmyeloablative, partially HLA-mismatched, T
cell-replete BMT that combines high-doseCy and stan-
dard postgrafting immunosuppression, greater HLA
disparity does not worsen overall outcome.
With MA related or unrelated donor BMT, do-
nor-recipient HLA incompatibility at either the sero-
logic or genotypic level has been associated with
lower relapse rates in some series [2,3,5,7].
For example, in patients with poor-risk leukemia
undergoing MA related donor BMT, 2- and 3-lo-
cus-mismatched transplants were associated with a
significantly lower relapse than HLA-identical sibling
transplants [3]. Likewise, in patients with poor-risk
leukemia or MDS undergoing MA related donor
BMT, significantly lower relapse was seen with 1
488 Biol Blood Marrow Transplant 16:482-489, 2010Y. L. Kasamon et al.antigen-mismatched versus no antigen-mismatched
grafts [5]. Following unrelated donor BMT, specific
combinations of allele mismatches have been linked
with lower relapse risk and improved overall survival,
not necessarily those that lead to severe aGVHD [4].
Typically, however, the potential antitumor benefit of
HLA disparity has been offset by higher rates of
GVHD and mortality.
Limitations of our analysis include its retrospective
nature and the small number of donor-recipient pairs
with fewer than 3 HLA mismatches (26, or 14% at
the antigen level). In particular, analyses of NRM
and graft failure may be underpowered, given the rel-
atively low number of occurrences. The small number
of patients with fewer mismatches also may limit the
power to demonstrate minor differences in outcomes
based on the degree of HLA disparity. Nevertheless,
for the overall outcome of EFS, greater HLA disparity
appeared to be not only nondetrimental, but actually
protective. This could be a chance finding, but it is un-
likely that a worsening of overall outcome would have
been missed.
We attempted to analyze potential confounding
variables and imbalances in patient characteristics
that could skew the data, and this did not change the
conclusions regarding EFS in relation to HLA dispar-
ity. Although it is possible that variables other than
those evaluated influenced the results, this is a limita-
tion of any comparative study. This may explain the
unexpected observation that having a female donor
for a male recipient was associated with inferior EFS
in the absence of a statistically significant increased
risk of acute GVHD.
We found no statistically significant association be-
tween the incidence of acute grade II or higher GVHD
and having more mismatches. Dissociation of an allo-
geneic GVT effect and GVHD remains an elusive
goal [26].Determiningwhethermismatches at particu-
lar loci are associatedwith differential risk ofGVHDor
relapse is beyond the scope of this study, and the anal-
yses of aGVHDcould be underpowered.Nevertheless,
our results raise the possibility that antitumor effects of
this particular transplantation platform can occur, re-
gardless of clinically significant aGVHD.Unlike calci-
neurin inhibitors, which block both T cell activation
and inductionof tolerance to alloantigens [27], the stra-
tegic delivery of high-dose Cy allows for the effective
deletion of proliferating alloreactive cells [12]. It may
be that posttransplantation Cy selectively kills cells re-
active to abundant alloantigens while minimally affect-
ing cells reactive to tumor-specific antigens, or that Cy
is more toxic to cells that cause GVHD than to cells
that cause GVT effects [28,29]. Potential effectors of
antitumor immunity include HLA class II-reactive
CD41 T cells, HLA class I-reactive CD81 T cells,
and natural killer (NK) cells that recognize missing
self [30-32]. Further studies are needed to define thesemechanisms and how the impact of HLA disparity dif-
fers according to disease entity and the vector of the
mismatch.
Compared with MA conditioning regimens, re-
duced-intensity conditioning regimens for allogeneic
BMT have been associated with lower incidences of
NRM [33] and GVHD [34], but with higher inci-
dences of graft failure [35] and relapse [36,37].
Although the incidences of NRM and GVHD were
acceptably low, the relatively high rates of graft failure
and relapse in this study suggest that the transplanta-
tion regimen can be further optimized. We are cur-
rently exploring strategies to reduce the incidences of
graft failure and relapse without increasing transplan-
tation-related toxicity; potential approaches include
enhancing the antitumor activity of the conditioning
regimen, immunizing donors against tumor-specific
antigens, and infusing alloreactive donor NK cells
after transplantation.
We view our observations in this study as hypothe-
sis-generating. Prospective studies are needed to
validate the findings.Nonetheless, this exploratory anal-
ysis raises the possibility that in patients who lack an
HLA-matched donor, the choice of a partially mis-
matched donor may not be dictated solely by the extent
of HLA disparity between donor and recipient. For pa-
tientswithmore thanone potentialHLA-haploidentical
donor, non-HLA characteristics of the graft that affect
its antitumor activity also may be considered during
donor selection. Examples include selecting grafts
according to killer cell immunoglobulin-like receptors
or, for patients with B cell lymphomas, according to
Fc receptor polymorphisms associated with greater
responsiveness to rituximab [38].ACKNOWLEDGMENTS
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